Illumina
Open
$160.89
Prev. Close
$161.29
High
$161.29
Low
$160.74
Market Snapshot
$24.61B
28.9
-7.67
$4.37B
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,600 full-time employees. The company went IPO on 2000-06-28. The firm's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. The company also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.
Illumina recently reported significant growth, highlighting advancements in genomic sequencing technology as demand for personalized medicine continues to rise in the biotechnology industry.
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,600 full-time employees. The company went IPO on 2000-06-28. The firm's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. The company also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.
Recently from Cashu
Illumina Launches StrataMap Spatial Solution to Advance Genomic Research and Enhance Analysis Efficiency
Illumina Inc (Ticker: ILMN) continues to push the boundaries of genomic research with the launch of its StrataMap Spatial Solution, a cutting-edge platform that enhances sequencing-based spatial trans…
Illumina Partners with IDT to Enhance Oncology Sequencing and Improve Cancer Care Solutions
In a strategic move to enhance its offerings in the oncology sequencing sector, Illumina, Inc. (Ticker: ILMN) forges a significant partnership with Integrated DNA Technologies (IDT). This collaboratio…
Illumina Launches MRD Research Kit to Enhance Cancer Detection and Patient Monitoring
Illumina Inc (Ticker: ILMN) strengthens its commitment to oncology with the recent launch of a novel molecular residual disease (MRD) research kit. Announced on May 28, 2026, this solution is the firs…
Illumina's 2025 Corporate Responsibility Report Highlights Global Genomics Access and Sustainability Achievements
Illumina Inc. (Ticker: ILMN) has published its 2025 Corporate Responsibility Report, highlighting its dedication to enhancing global access to genomics and achieving ambitious sustainability milestone…